2 minute read | October.04.2023
Clinical-stage biotech company Kineta has announced a registered direct offering of more than 890,000 shares of common stock expected to generate $3 million in gross proceeds.
Orrick represented Kineta, which focuses on the development of novel immunotherapies in oncology to address cancer immune resistance.
Kineta is on a mission to develop next-generation immunotherapies that transform patients’ lives.
The company has leveraged its expertise in innate immunity. It focuses on discovering and developing potentially differentiated immunotherapies that address the major challenges with cancer therapy.
Kineta said it plans to use the net proceeds for working capital purposes.